Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: A systematic review and meta-analysis of clinical trials

Amirhossein Sahebkar; L.E. Simental-Mendía; F. Guerrero-Romero; J. Golledge; Gerald Watts

doi:10.1111/dom.12536

Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: A systematic review and meta-analysis of clinical trials

Amirhossein Sahebkar, L.E. Simental-Mendía, F. Guerrero-Romero, J. Golledge, Gerald Watts

Graduate Research School

Research output: Contribution to journal › Article › peer-review

72 Citations (Scopus)

Abstract

© 2015 John Wiley & Sons Ltd. Aims: To evaluate the magnitude of the effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) levels through a systematic review and meta-analysis of clinical trials. Methods: A random-effects model (using DerSimonian-Laird method) and the generic inverse variance method were used for quantitative data synthesis. Heterogeneity was quantitatively assessed using the I2 index. Sensitivity analyses were conducted using the one-study remove approach. Random-effects meta-regression was performed using an unrestricted maximum likelihood method to evaluate the association between statin-induced elevation of plasma PCSK9 concentrations with duration of treatment and magnitude of LDL cholesterol reduction. Results: A total of 15 clinical trials examining the effects of statin therapy on plasma PCSK9 levels were included. Meta-analysis of data from single-arm statin treatment arms [weighted mean difference (WMD) 40.72ng/ml, 95% confidence interval (CI) 34.79, 46.65; p

Original language	English
Pages (from-to)	1042-1055
Journal	Diabetes, Obesity and Metabolism
Volume	17
Issue number	11
DOIs	https://doi.org/10.1111/dom.12536
Publication status	Published - 2015

Access to Document

10.1111/dom.12536

Cite this

@article{ff60e86f50474b2c9b849826807f073c,

title = "Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: A systematic review and meta-analysis of clinical trials",

abstract = "{\textcopyright} 2015 John Wiley & Sons Ltd. Aims: To evaluate the magnitude of the effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) levels through a systematic review and meta-analysis of clinical trials. Methods: A random-effects model (using DerSimonian-Laird method) and the generic inverse variance method were used for quantitative data synthesis. Heterogeneity was quantitatively assessed using the I2 index. Sensitivity analyses were conducted using the one-study remove approach. Random-effects meta-regression was performed using an unrestricted maximum likelihood method to evaluate the association between statin-induced elevation of plasma PCSK9 concentrations with duration of treatment and magnitude of LDL cholesterol reduction. Results: A total of 15 clinical trials examining the effects of statin therapy on plasma PCSK9 levels were included. Meta-analysis of data from single-arm statin treatment arms [weighted mean difference (WMD) 40.72ng/ml, 95% confidence interval (CI) 34.79, 46.65; p",

author = "Amirhossein Sahebkar and L.E. Simental-Mend{\'i}a and F. Guerrero-Romero and J. Golledge and Gerald Watts",

year = "2015",

doi = "10.1111/dom.12536",

language = "English",

volume = "17",

pages = "1042--1055",

journal = "Diabets, Obesity and Metabolism",

issn = "1462-8902",

publisher = "Wiley-Blackwell",

number = "11",

}

Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: A systematic review and meta-analysis of clinical trials. / Sahebkar, Amirhossein; Simental-Mendía, L.E.; Guerrero-Romero, F. et al.
In: Diabetes, Obesity and Metabolism, Vol. 17, No. 11, 2015, p. 1042-1055.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: A systematic review and meta-analysis of clinical trials

AU - Sahebkar, Amirhossein

AU - Simental-Mendía, L.E.

AU - Guerrero-Romero, F.

AU - Golledge, J.

AU - Watts, Gerald

PY - 2015

Y1 - 2015

N2 - © 2015 John Wiley & Sons Ltd. Aims: To evaluate the magnitude of the effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) levels through a systematic review and meta-analysis of clinical trials. Methods: A random-effects model (using DerSimonian-Laird method) and the generic inverse variance method were used for quantitative data synthesis. Heterogeneity was quantitatively assessed using the I2 index. Sensitivity analyses were conducted using the one-study remove approach. Random-effects meta-regression was performed using an unrestricted maximum likelihood method to evaluate the association between statin-induced elevation of plasma PCSK9 concentrations with duration of treatment and magnitude of LDL cholesterol reduction. Results: A total of 15 clinical trials examining the effects of statin therapy on plasma PCSK9 levels were included. Meta-analysis of data from single-arm statin treatment arms [weighted mean difference (WMD) 40.72ng/ml, 95% confidence interval (CI) 34.79, 46.65; p

AB - © 2015 John Wiley & Sons Ltd. Aims: To evaluate the magnitude of the effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) levels through a systematic review and meta-analysis of clinical trials. Methods: A random-effects model (using DerSimonian-Laird method) and the generic inverse variance method were used for quantitative data synthesis. Heterogeneity was quantitatively assessed using the I2 index. Sensitivity analyses were conducted using the one-study remove approach. Random-effects meta-regression was performed using an unrestricted maximum likelihood method to evaluate the association between statin-induced elevation of plasma PCSK9 concentrations with duration of treatment and magnitude of LDL cholesterol reduction. Results: A total of 15 clinical trials examining the effects of statin therapy on plasma PCSK9 levels were included. Meta-analysis of data from single-arm statin treatment arms [weighted mean difference (WMD) 40.72ng/ml, 95% confidence interval (CI) 34.79, 46.65; p

U2 - 10.1111/dom.12536

DO - 10.1111/dom.12536

M3 - Article

C2 - 26183252

SN - 1462-8902

VL - 17

SP - 1042

EP - 1055

JO - Diabets, Obesity and Metabolism

JF - Diabets, Obesity and Metabolism

IS - 11

ER -

Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: A systematic review and meta-analysis of clinical trials

Abstract

Access to Document

Fingerprint

Cite this